ABLYNX (OTCMKTS:ABLYF) – Investment analysts at Jefferies Group boosted their FY2021 earnings per share (EPS) estimates for ABLYNX in a note issued to investors on Wednesday. Jefferies Group analyst P. Welford now expects that the company will post earnings of $1.10 per share for the year, up from their previous estimate of $1.05.
Other analysts have also issued research reports about the company. Zacks Investment Research lowered ABLYNX from a “buy” rating to a “hold” rating in a research report on Thursday. Bank of America assumed coverage on ABLYNX in a research report on Friday, November 10th. They set a “buy” rating and a $26.00 price objective on the stock.
ABLYNX Company Profile
Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.
Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.